Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.33 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 12/20 | 0.31 |
| ▸ | JAK2 | O60674 | 12/20 | 0.31 |
| ▸ | JAK3 | P52333 | 6/20 | 0.31 |
| ▸ | TYK2 | P29597 | 4/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22736207 | 0.83 | JAK1 (0.37) | JAK1JAK2JAK3TYK2 | |
| SCHEMBL22735724 | 0.82 | JAK1 (0.36) | JAK1JAK2 | |
| SCHEMBL22735725 | 0.76 | JAK2 (0.33) | AURKAAURKBINCENPTPX2JAK1 | |
| SCHEMBL22735727 | 0.73 | JAK2 (0.38) | AURKAAURKBINCENPTPX2JAK1 | |
| SCHEMBL29480630 | 0.72 | FGFR4 (0.35) | JAK1JAK2JAK3 | |
| SCHEMBL22736467 | 0.72 | JAK2 (0.35) | AURKAAURKBINCENPTPX2JAK1 | |
| SCHEMBL22735995 | 0.71 | CCNT1 (0.34) | — | |
| SCHEMBL29480545 | 0.70 | BTK (0.39) | AURKAAURKBINCENPTPX2JAK1 | |
| SCHEMBL22736479 | 0.70 | JAK2 (0.36) | AURKAAURKBINCENPTPX2JAK1 | |
| SCHEMBL22736471 | 0.69 | JAK2 (0.35) | JAK1JAK2JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976612-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | MANKIND PHARMA LTD (IN) | 2022-04-06 | — | — | EP | claimed |
| CN-114174294-A | Novel compounds for inhibiting JANUS kinase 1 | 人类制药有限公司 | 2022-03-11 | — | — | CN | claimed |
| US-12516056-B2 | Compounds for inhibition of janus kinase 1 | MANKIND PHARMA LTD. (IN) | 2026-01-06 | — | — | US | disclosed |
| CN-114174294-B | Novel compounds for inhibiting JANUS kinase 1 | 人类制药有限公司 | 2024-10-25 | — | — | CN | disclosed |
| US-20220235046-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | MANKIND PHARMA LTD. (IN) | 2022-07-28 | — | — | US | disclosed |
| EP-3976612-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | MANKIND PHARMA LTD (IN) | 2022-04-06 | — | — | EP | disclosed |
| CN-114174294-A | Novel compounds for inhibiting JANUS kinase 1 | 人类制药有限公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235046-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | JAK1, JAK2, JAK3 | AURKA 222/4885AURKB 325/4885INCENP 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.